UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

Form 10-Q

[  X  ] Quarterly Report pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934

For the quarterly period ended June 30, 2003

[   ] Transition Report Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934

For the transition period from ___ to ___

Commission File Number  0-26138

1200 Mount Kemble Avenue
Morristown, NJ 07960
————————————————————
(Address, including zip code, of
principal executive offices)

(973) 425-1200
————————————————————
(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    [  X  ]

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act):     [  X  ]

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the last practicable date: at August 11, 2003 there were 40,419,646 shares of common stock outstanding.

DENDRITE INTERNATIONAL, INC.
INDEX

2

PART I.      FINANCIAL INFORMATION

ITEM 1.      Financial Statements

DENDRITE INTERNATIONAL, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(IN THOUSANDS, EXCEPT PER SHARE DATA)
(UNAUDITED)

The accompanying notes are an integral part of these statements.

3

DENDRITE INTERNATIONAL, INC.
CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS, EXCEPT SHARE DATA)

The accompanying notes are an integral part of these statements.

4

DENDRITE INTERNATIONAL, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(IN THOUSANDS)
(UNAUDITED)

The accompanying notes are an integral part of these statements.

5

DENDRITE INTERNATIONAL, INC.
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

1. Basis of Presentation

        The consolidated financial statements of Dendrite International, Inc. and its subsidiaries (the “Company”) included in this Form 10-Q are unaudited and reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for a fair presentation of the financial position and operating results for the three and six month periods ended June 30, 2003 and 2002. For further information, refer to the consolidated financial statements and notes thereto included in the Company’s Annual Report on Forms 10-K and 10-K/A for the year ended December 31, 2002.

        Our interim operating results may not be indicative of operating results for the full year.

2. Net Income Per Share

        Basic net income per share was computed by dividing the net income for each period by the weighted average number of shares of common stock outstanding for each period. Diluted net income per share was computed by dividing net income for each period by the weighted average number of shares of common stock and common stock equivalents (stock options) outstanding during each period. For the three and six months ended June 30, 2003 common stock equivalents used in computing diluted net income per share were 880,000 and 589,000 shares, respectively. For the three and six months ended June 30, 2002 common stock equivalents used in computing diluted net income per share were 400,000 and 451,000 shares, respectively.

3. Comprehensive Income

        Assets and liabilities of the Company’s wholly-owned international subsidiaries are translated at their respective period-end exchange rates and revenues and expenses are translated at average currency exchange rates for the period. The resulting foreign currency translation adjustments from assets and liabilities are included as “Accumulated other comprehensive loss” and are reflected as a separate component of stockholders’ equity. Total after-tax comprehensive income, which is calculated by adding the foreign currency translation adjustment to net income, for the three months ended June 30, 2003 was $6,139,000 compared to $4,874,000 for the three months ended June 30, 2002. Total after-tax comprehensive income for the six months ended June 30, 2003 was $10,334,000 compared to $8,207,000 for the six months ended June 30, 2002.

4. Reclassifications

        Certain prior period balances have been reclassified to conform with current year presentation.

5. Stock Based Compensation

        The Company has adopted the disclosure requirements of Statement of Financial Accounting Standards (“SFAS”) 123, “Accounting for Stock-Based Compensation”, as amended by SFAS 148 “Accounting for Stock-Based Compensation – Transition and Disclosure”. The Company applies Accounting Principles Board (“APB”) 25, “Accounting for Stock Issued to Employees” and related interpretations in accounting for stock options granted under the Company’s stock option plans (the “Plans”). Accordingly, compensation cost has been computed for the Plans based on the intrinsic value of the stock option at the date of grant, which represents the difference between the exercise price and the fair value of the Company’s stock. As the exercise price of all stock options granted equaled the fair value of the Company’s stock at the date of option issuance, no compensation cost related to stock options has been recorded in the accompanying statements of operations. Had compensation cost for the Plans and the employee stock purchase plan been determined consistent with SFAS 123, the Company’s net income and net income per share would have been adjusted to the following pro forma amounts:

6

6. Restructuring Charge

        The activity in accrued restructuring as of June 30, 2003 is summarized in the table below:

7. Acquisitions

        On September 19, 2002, the Company acquired Software Associates International (“SAI”), a privately-held company based in New Jersey. SAI provided software products and solutions that enhanced corporate level sales and marketing analysis for pharmaceutical companies. These solutions are complementary to the Company’s core suite of business products. The results of SAI’s operations have been included in the Consolidated Financial Statements since the acquisition date.

        The aggregate purchase price was approximately $16,739,000 which included: cash of approximately $15,092,000 (approximately $1,600,000 in escrow as of June 30, 2003); accrued professional service fees of approximately $410,000; and options to purchase Dendrite common stock valued at approximately $1,237,000. The fair value of the stock options was estimated using the Black-Scholes valuation model. The Company is in the process of finalizing a third-party valuation of certain intangible assets and its own evaluation of acquired facilities, and therefore, the purchase price allocation is preliminary and subject to adjustment.

        On June 16, 2003, the Company completed its acquisition of Synavant Inc. (“Synavant”). Synavant provided a broad range of knowledge-based services to biopharmaceutical and healthcare companies around the world. Its comprehensive global solutions included pharmaceutical Customer Relationship Management (CRM) and e-Business applications, interactive marketing, server and database management, dedicated local helpline support, training, telemarketing, sample management, and product recall services. Synavant was headquartered in Atlanta, Georgia and had offices in 21 countries. The combining of the resources of Synavant with Dendrite created a comprehensive information, software, and services company dedicated to the global pharmaceutical industry, and further enhanced Dendrite’s ability to provide market leading solutions to the sales, marketing and clinical functions of pharmaceutical and other life science companies. The results of Synavant’s operations have been included in the accompanying Consolidated Financial Statements since the date of acquisition.

        The Synavant acquisition was completed pursuant to an Agreement and Plan of Merger, dated as of May 9, 2003 and amended as of May 16, 2003 (as amended, the “Merger Agreement”) by and among Dendrite, Synavant, and Amgis Acquisition Co. (“Amgis”), a wholly-owned subsidiary of Dendrite. Amgis and Dendrite conducted an all cash tender offer followed by a second step merger, to acquire all of the outstanding shares of common stock of Synavant, at a price of $3.22 per share. The consideration paid in the acquisition was a result of a bidding process and arms-length negotiations between the executive officers and the boards of directors of Synavant and Dendrite.

        The aggregate purchase price was approximately $54,813,000 and included consideration paid for the common stock and approximately $3,128,000 of legal and professional fees incurred in connection with the transaction.

        A condensed balance sheet of Synavant, reflecting the amount assigned to each major asset and liability category as of June 16, 2003 is as follows (thousands):

7

        In connection with the Synavant acquisition, the Company recorded $56,101,000 of goodwill and $29,900,000 of acquired intangible assets of which approximately $6,000,000 was assigned to Trademarks, which are not subject to amortization. The remaining $23,900,000 (approximately 11 year weighted average amortization period) has been assigned to the following intangible assets: non-compete agreements — $2,100,000 (3 year amortization); backlog — $4,500,000 (3 year amortization); purchased capitalized software — $2,600,000 (10 year amortization); and customer relationships — $14,700,000 (15 year amortization). The goodwill and intangible assets recorded for financial statement purposes are not deductible for tax purposes. The Company is in the process of finalizing a third party valuation of certain intangible assets, as well as its evaluation of acquired facilities and personnel for redundancy and, therefore, the purchase price allocation is preliminary and subject to adjustment.

8

        Pro-forma results of operations of the Company as if the Synavant and SAI acquisitions had occurred as of January 1, 2002 for the three and six month periods ended June 30, 2003 are as follows:

(A) Net income (loss) includes approximately $500,000 of restructuring charges from Synavant as well as early termination fees related to Synavant’s lines of credit of approximately $800,000

(B) Net income (loss) includes approximately $1,300,000 of restructuring charges from Synavant as well as early termination fees related to Synavant’s lines of credit of approximately $1,850,000

8. Purchase Accounting Restructuring Accrual

        In connection with the acquisition of SAI, discussed in Note 7, the Company developed an exit plan to close SAI’s facility in Mt. Arlington, New Jersey and to relocate the operations to other Company facilities in New Jersey. The Company accrued as part of the acquisition costs the costs to terminate certain leases amounting to $3,252,000. The Company exited the facility during the first quarter of 2003. The activity related to the SAI purchase accounting restructuring accrual as of June 30, 2003 is summarized in the table below:

        In connection with the acquisition of Synavant, discussed in Note 7, the Company plans to restructure the Synavant operations, to exit certain facilities of Synavant and to terminate the employment of certain Synavant employees in connection with the restructuring. The Company has accrued approximately $22,102,000 at June 16, 2003 for liabilities associated with the cost of completing the restructuring plan. The components of this accrued liability are as follows; severance costs for Synavant employees being involuntarily terminated as a result of the acquisition — approximately $13,042,000 and costs to exit facilities for Synavant facilities being vacated as a result of the acquisition — approximately $9,060,000.

        The liability accrued for expenses incurred in exiting certain facilities of Synavant includes assumptions related to sublease income offsetting future lease obligations. The underlying subleases are not in place for all facilities and the future placement of subleases including timing of subleases and terms and conditions of subleases could be different than the assumptions.

        The Company anticipates that the majority of the accrued restructuring balance relating to terminated employees will be utilized during 2004. The activity related to the Synavant purchase accounting restructuring accrual as of June 30, 2003 is summarized in the table below:

9

9. Goodwill and Intangible Assets

         Effective January 1, 2002 the Company adopted SFAS 142, “Goodwill and other Intangible Assets.” SFAS 142 requires that goodwill and certain intangibles no longer be amortized, but instead be tested for impairment at least annually. SFAS 142 also requires that intangible assets with finite useful lives be amortized over their respective estimated useful lives and reviewed for impairment in accordance with SFAS 121, which was superceded by SFAS 144. Based on the Company’s analysis, there was no impairment of goodwill upon adoption of SFAS 142 on January 1, 2002. The Company conducts its annual impairment testing of goodwill on October 1 of each year. For the year ended December 31, 2002 there was no impairment recorded.

        The total gross carrying amount and accumulated amortization for goodwill and intangible assets are as follows:

        The activity in the carrying amount of goodwill for the six month period ended June 30, 2003 is as follows:

10

        Aggregate annual amortization expense for intangible assets is estimated to be:

10. Line of Credit

        The Company entered into a credit agreement (the “Agreement”) as of June 16, 2003, in the amount of $30 million with JPMorgan Chase Bank as the agent. The Agreement replaces the $15 million credit facility, which was terminated. The Agreement is available to finance working capital needs and possible future acquisitions. The terms of this Agreement require the Company to maintain a minimum consolidated net worth, among other covenants, measured quarterly, which is equal to $130 million, plus 50% of net income earned after April 1, 2003 and 75% of net proceeds of any offering of new equity interests issued after June 30, 2003. This covenant effectively limits the amount of any cash dividends. The Agreement expires on July 1, 2005. During the second quarter of 2003, the Company borrowed $5,000,000 from the line of credit under the Agreement, which was repaid prior to June 30, 2003. At June 30, 2003, there were no borrowings outstanding under the Agreement and the Company was in compliance with all of covenant obligations.

11. Customer and Geographic Segment Data

        For the three months ended June 30, 2003 and 2002, the Company derived approximately 44% of its revenues from its largest customer and approximately 46% of its revenues from its largest two customers, respectively. For the six months ended June 30, 2003 and 2002, the Company derived approximately 45% of its revenues from its largest customer, and approximately 55% of its revenues from its three largest customers, respectively.

        The Company is organized by geographic locations and has one reportable segment. All transfers between geographic areas have been eliminated from consolidated revenues. Operating income consists of total revenues recorded in the location less operating expenses and does not include interest income, other expense or income taxes. This data is presented in accordance with SFAS 131, “Disclosure About Segments of an Enterprise and Related Information.”

        For segment reporting purposes, license revenues have been allocated to the sales office of the respective country in which the sale is made, although the actual contract is with the U.S. entity for legal and tax purposes.

12. Income Taxes

        In connection with the integration of the Synavant acquisition discussed in Note 7, the Company performed a reforecast of projected taxable income by jurisdiction and recognized a full valuation allowance on net operating loss carry forward for one of its foreign subsidiaries of approximately $608,000.

13. Recent Accounting Pronouncements

        In November 2002, the FASB issued EITF Issues 00-21, “Accounting for Revenue Arrangements with Multiple Deliverables” (“EITF 00-21”). EITF 00-21 addresses the accounting for arrangements that involve the delivery or performance of multiple products, services or rights to use assets. This consensus is applicable to arrangements entered after June 15, 2003. The Company adopted EITF 00-21 on June 15, 2003, and it did not have a material impact on its consolidated financial statements.

11

ITEM 2.      Management’s Discussion and Analysis of Financial Condition and Results of Operations.

FORWARD-LOOKING STATEMENTS

        This Form 10-Q may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21-E of the Securities Exchange Act of 1934, which are intended to be covered by the safe harbors created by such acts. For this purpose, any statements that are not statements of historical fact may be deemed to be forward-looking statements, including the statements under “Management’s Discussion and Analysis of Financial Condition and Results of Operations” regarding our strategy, future operations, future expectations or future estimates, future financial position and future plans and objectives of management. Those statements in this Form 10-Q containing the words “believes”, “anticipates”, “plans”, “expects” and similar expressions constitute forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on our current expectations, assumptions, estimates and projections about our Company and the pharmaceutical and consumer packaged goods industries. All such forward-looking statements involve significant risks and uncertainties, including those risks identified in this Form 10-Q under “Factors That May Affect Future Operating Results”, many of which are beyond our control. Although we believe that the assumptions underlying our forward-looking statements are reasonable, any of the assumptions could be inaccurate and actual results may differ materially from those indicated by the forward-looking statements included in this Form 10-Q, as more fully described under “Factors That May Affect Future Operating Results”. In light of the significant uncertainties inherent in the forward-looking statements included in this Form 10-Q, you should not consider the inclusion of such information as a representation by us or anyone else that we will achieve such results. Moreover, we assume no obligation to update these forward-looking statements to reflect actual results. In addition, our financial and performance outlook concerning future revenues, margins, earnings and earnings per share and other operating or performance results does not include the impact of any future acquisitions or future acquisition-related expenses or any future restructuring or other charges that may occur from time to time due to management decisions and changing business circumstances and conditions.

OVERVIEW

         Co-founded in 1986 by John E. Bailye, the Company’s Chairman and Chief Executive Officer, and incorporated in 1987, Dendrite was established to provide sales force automation solutions for the pharmaceutical industry. Since then, it has broadened its offerings to include multiple sales and marketing solutions and related services to life sciences clients. Dendrite’s solutions now comprise a broad array of knowledge-based, technology-driven solutions that increase the effectiveness of sales, marketing, and clinical processes for pharmaceutical and other life sciences clients, including: Customer Relationship Management (CRM) Solutions, Information Management, Business Intelligence and Analytics, and Commercial Operations Management.

        Dendrite’s primary markets are the United States, the United Kingdom, France, Spain and Japan. We bill services provided by our foreign branches and subsidiaries in local currencies. Operating results generated in local currencies are translated into U.S. dollars at the average exchange rate in effect for the reporting period. We generated approximately 19% of our total revenues outside the United States during each of the six months ended June 30, 2003 and 2002. Our operating profits by geographic segment are shown in Note 11 of the Notes to Unaudited Consolidated Financial Statements.

CRITICAL ACCOUNTING POLICIES, JUDGMENTS AND ESTIMATES

        Securities and Exchange Commission Financial Reporting Release 60 requires companies to include a discussion of critical accounting policies or methods used in the preparation of financial statements. A critical accounting policy is one that is both very important to the portrayal of a company’s financial position and results of operations, and requires management’s most difficult, subjective or complex judgments. The Company believes its critical accounting policies to be revenue recognition, accounting for restructuring, acquisitions, impairments and income taxes.

Revenue Recognition
        The area of revenue recognition requires the Company’s management to make significant judgments and estimates. AICPA Statement of Position (SOP) 97-2, “Software Revenue Recognition”, governs revenue recognition for arrangements that include software which is more than incidental to the arrangement. Under SOP 97-2, if a sale of software includes services that are essential to the functionality of the software, then the entire arrangement is to be accounted for using contract accounting as described in Accounting Research Bulletin 45, “Long-Term Construction-Type Contracts”, and SOP 81-1, “Accounting for Performance of Construction-Type and Certain Production-Type Contracts.” The determination of whether or not services are essential to the functionality of the software can differ from arrangement to arrangement, and requires the use of significant judgment by management. Factors used in determining whether or not services are essential to the functionality may include: whether or not physical changes are being made to the software’s underlying source code; the complexity of software configuration services; the level of effort required to build interfaces; the overall relationship of the service fees to the license fees; the length of time expected to complete the services and whether or not the services can be obtained by a customer from their internal resources or another third-party vendor. If services are not considered to be essential to the software, SOP 97-2 generally allows companies to recognize revenue for software licenses upon delivery of the licenses, prior to configuration or implementation services, provided that the other requirements of the SOP are met. In management’s judgment, the Company’s configuration and implementation services generally are essential to the functionality of its software. Therefore, the Company typically recognizes revenues using the percentage-of-completion method as detailed in SOP 81-1.

12

        The Company’s arrangements are segmented, in accordance with SOP 81-1, into two primary elements or profit centers, one being the license fee and implementation service element and the other being an ongoing sales force support services element. The Company believes that its arrangements meet all of the criteria under SOP 81-1 to allow for the segmentation of the two elements. If the segmentation criteria could not be met, it would result in recognition of the Company’s license and implementation service revenues over the term of its multi-year support service agreements.

        The percentage-of-completion method of revenue recognition requires management to use significant estimates in measuring the progress-to-completion for each project. For its license fee and implementation service projects, the Company uses the input measure of labor incurred as compared with total expected labor for the entire project. The determination of total project labor requires the use of significant judgment and estimates. We review these estimates on a monthly basis. Actual results could differ from these estimates, which would have impacted the amount of revenue previously recognized, had better estimates been available at the time.

Accounting for Restructuring
        During 2001, the Company recognized costs in connection with a restructuring plan, which involved a reduction in size of the Company’s work force, downsizing of certain facilities and relocation of certain activities. During 2002, in connection with the purchase accounting related to the acquisition of SAI, the Company established an accrual related to costs in connection with exiting SAI’s facility. During 2003, in connection with the purchase accounting related to the acquisition of Synavant, the Company established an accrual related to costs in connection with exiting multiple Synavant facilities as well as a reduction in the size of the work force.

Accounting for Acquisitions
        The purchase combinations carried out by us require management to estimate the fair value of the assets acquired and liabilities assumed in the combinations. These estimates of fair value are based on our business plan for the entities acquired including planned redundancies, restructuring, use of assets acquired and assumptions as to the ultimate resolution of obligations assumed for which no future benefit will be received. We also utilize appraisal reports issued by independent appraisers. Should actual use of assets or resolution of obligations differ from our estimates, revisions to the estimated fair values would be required.

Accounting for Impairments
        We review long-lived assets other than goodwill for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset might not be recoverable. If indicators of impairment are present, we evaluate the recoverability of the long-lived assets by estimating future undiscounted cash flows that are directly associated with and that are expected to arise as a direct result of the use and eventual disposition of the long-lived asset. If this estimate of future undiscounted cash flows demonstrates that recoverability is not probable, an impairment loss would be calculated and recognized. An impairment loss would be calculated based on the excess carrying amount of the long-lived asset over the long-lived asset’s fair value. The estimate of the fair value and the future undiscounted cash flows of the underlying long-lived assets are based on significant judgment and assumptions.

        We review capitalized software development costs and purchased capitalized development software costs for impairment at each balance sheet date to determine if the unamortized capitalized costs of a computer software product is greater than the net realizable value of that product. In those instances where the unamortized capitalized costs are greater than the net realizable value, we will record an impairment.

        We assess the impairment of goodwill and indefinite lived intangibles on an annual basis (October 1 of each year), and whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Some factors we consider important which could trigger an impairment review include the following:

        On an annual basis, or when we determine that the carrying value of goodwill and indefinite lived intangibles may not be recoverable based upon the existence of one or more of the above indicators of impairment, we compare the fair value of the reporting unit to its carrying value, including goodwill (step one of the required test). If the carrying value exceeds fair value, we would perform step two of the required test. Under step two, we would calculate the implied fair value of the goodwill for the reporting unit and compare it to the carrying value of the goodwill for the reporting unit. If the implied fair value of the goodwill is less than the carrying value of the goodwill, we would recognize in our Statement of Operations an impairment loss equal to such difference, not to exceed the carrying value.

13

Accounting for Income Taxes
        We recognize deferred tax assets and liabilities based on the differences between the financial statement carrying amounts and the tax bases of assets and liabilities. The Company regularly reviews its deferred tax assets for recoverability and establishes a valuation allowance based on historical taxable income, projected future taxable income, and the expected timing of the reversals of existing temporary differences, all of which require significant management judgments. Realization is dependent on generating sufficient taxable income of a correct character prior to the expiration of the loss carryforwards, capital loss and foreign tax credit carryforwards. Although realization is not assured, management currently believes it is more likely than not that the recorded net deferred tax asset will be realized; however, the asset could be reduced in the near term if estimates of future taxable income during the carryforward period are reduced.

RECENT DEVELOPMENTS

        On June 16, 2003, the Company completed its acquisition of Synavant. Synavant provided a broad range of knowledge-based services to biopharmaceutical and healthcare companies around the world. Its comprehensive global solutions included pharmaceutical Customer Relationship Management (CRM) and e-Business applications, interactive marketing, server and database management, dedicated local helpline support, training, telemarketing, sample management, and product recall services. Synavant was headquartered in Atlanta, Georgia, USA and had offices in 21 countries. The combining of the resources of Synavant with Dendrite created a comprehensive information, software, and services company dedicated to the global pharmaceutical industry, and further enhanced Dendrite’s ability to provide market leading solutions to the sales, marketing and clinical functions of pharmaceutical and other life science companies. The results of Synavant’s operations have been included in the accompanying Consolidated Financial Statements since the date of acquisition.

        The acquisition was completed pursuant to an Agreement and Plan of Merger, dated as of May 9, 2003 and amended as of May 16, 2003 (as amended, the “Merger Agreement”) by and among Dendrite, Synavant, and Amgis Acquisition Co. (“Amgis”), a wholly-owned subsidiary of Dendrite. Amgis and Dendrite conducted an all cash tender offer followed by a second step merger to acquire all of the outstanding shares of common stock of Synavant, at a price of $3.22 per share. The consideration paid in the acquisition was a result of a bidding process and arms-length negotiations between the executive officers and the boards of directors of Synavant and Dendrite.

        The aggregate purchase price was approximately $54,813,000 and included consideration paid for the common stock and approximately $3,128,000 of legal and professional fees incurred in connection with the transaction. The Company is in the process of finalizing a third party valuation of certain intangible assets, its evaluation of acquired facilities and personnel for redundancy and, therefore, the purchase price allocation is preliminary and subject to adjustment.

        In connection with the acquisition of Synavant the Company plans to restructure the Synavant operations, to exit certain facilities of Synavant and to terminate the employment of certain Synavant employees in connection with the restructuring. The Company has accrued approximately $22,102,000 at June 16, 2003 for liabilities associated with the cost of completing the restructuring plan. The components of this accrued liability are as follows; severance costs for Synavant employees being involuntarily terminated as a result of the acquisition — approximately $13,042,000 and costs to exit facilities for Synavant facilities being vacated as a result of the acquisition — approximately $9,060,000.

        The liability accrued for expenses incurred in exiting certain facilities of Synavant includes assumptions related to sublease income offsetting future lease obligations. The underlying subleases are not in place for all facilities and the future placement of subleases including timing of subleases and terms and conditions of subleases could be different than the assumptions.

RESULTS OF OPERATIONS

        In the following discussion of the Company’s results of operations includes the results of Synavant for the period from the June 16, 2003 acquisition date. The following discussion of our results of operations also, where indicated, segregates the results of Synavant. The discussion also reconciles the segregated Synavant results to total Company results. The Company believes that segregating Synavant’s results from the date of acquisition provides investors with useful information, on a comparative basis, on the impact of Synavant on overall Company operations for the three and six months ended June 30, 2003.

14

THREE MONTHS ENDED JUNE 30, 2003 AND 2002

            REVENUES. Total revenues increased to $69,528,000 in the three months ended June 30, 2003, up $11,916,000 or 21% from $57,612,000 in the three months ended June 30, 2002. Total revenues for the three months ended June 30, 2003 includes $7,426,000 of revenues recognized from Synavant subsequent to the Company’s acquisition. Due to the timing of several large deals within the quarter, Synavant performed a substantial amount of services during the last two weeks of the quarter which caused a higher than expected amount of revenue to be recognized. Excluding the revenue recognized from Synavant, revenues increased by $4,490,000, or 8%, in the three months ended June 30, 2003 over the prior year period.

        License fee revenues increased to $2,752,000 in the three months ended June 30, 2003, up $446,000 or 19% from $2,306,000 in the three months ended June 30, 2002. License fee revenues as a percentage of total revenues were 4% in the three months ended June 30, 2003 and June 30, 2002. License fee revenues for the three months ended June 30, 2003 includes $86,000 of revenues recognized from Synavant subsequent to the Company’s acquisition. Excluding the results of Synavant, license fee revenues increased $360,000, or 16% in the three months ended June 30, 2003 over the prior year period. The increase in license revenues was driven by additional users in our Japanese market.

        Service revenues increased to $66,776,000 in the three months ended June 30, 2003, up $11,470,000 or 21% from $55,306,000 in the three months ended June 30, 2002. Service revenues for the three months ended June 30, 2003 includes $7,340,000 of revenue recognized from Synavant subsequent to the Company’s acquisition. Excluding the results of Synavant, service revenues increased $4,130,000, or 7%, in the three months ended June 30, 2003 over the prior year period. This increase is a result of approximately 20% growth in our technical services revenue, approximately 19% increase in our international services, and growth in consulting and data businesses of more than 100%. This increase was offset by a decrease in our low gross margin or reimbursable revenue of approximately $2,464,000 to $1,025,000 for the three months ended June 30, 2003 from $3,489,000 in the three months ended June 30, 2002.

         COST OF REVENUES. Total cost of revenues increased to $34,782,000 in the three months ended June 30, 2003, up $6,027,000 or 21% from $28,755,000 in the three months ended June 30, 2002. Total cost of revenues in the three months ended June 30, 2003 includes $4,858,000 of costs recognized from Synavant subsequent to the acquisition. Excluding the results of Synavant, cost of revenues increased $1,169,000, or 4% for three months ended June 30, 2003 over the prior year period.

        Cost of license fees increased to $1,204,000 in the three months ended June 30, 2003, up $197,000 or 20% from $1,007,000 in the three months ended June 30, 2002. Cost of license fees for the three months ended June 30, 2003 is comprised of the amortization of capitalized and purchased software costs of $850,000 and third party-vendor license fees of $354,000. Cost of license fees for the same period in 2002 is comprised of the amortization of capitalized and purchased software costs of $648,000 and third party vendor license fees of $359,000. The increase in amortization of capitalized and purchased software costs relates primarily to amortization of the assets obtained from the acquisitions of SAI while third party vendor license fees remained relatively constant.

        Cost of services increased to $33,578,000 in the three months ended June 30, 2003, up $5,830,000 or 21% from $27,748,000 in the three months ended June 30, 2002. This increase was due primarily to a $4,858,000 incremental increase in cost of services related to the Synavant acquisition. Excluding the results of Synavant, cost of services for the period increased $972,000 or 4% over the prior year period. This increase is due to the additional costs from the increase in headcount due to the acquisition of SAI in September 2002 as well as additional outside consultants related to the integration work for our largest customer. These increases were offset by a decrease in low-gross margin or reimbursable revenue.

         GROSS MARGIN. Total gross margin for the three months ended June 30, 2003 and June 30, 2002 was 50%. Excluding the impact of Synavant, as discussed above, total gross margin for the three months ended June 30, 2003 was 52%.

        Gross margin for license fees was 56% in the three months ended June 30, 2003 and June 30, 2002. Excluding the result of Synavant, discussed above, gross margin for license fees was 55% for the three months ended June 30, 2003. The gross margin decreased slightly due primarily to an increase in amortization of capitalized and purchased software costs offset by the increase in license fee revenues.

        Gross margin for services was 50% in the three months ended June 30, 2003 and June 30, 2002. Excluding the results of Synavant discussed above, gross margin for the three months ended June 30, 2003 was 52%. The gross margin increased due to approximately 20% growth in our technical services revenue, approximately 19% growth in our international services and a decrease in the low gross margin or reimbursable revenue, offset by increase in employment costs related to the increase in headcount from the SAI acquisition as well as additional outside consultants related to the integration work for our largest customer.

         SELLING, GENERAL AND ADMINISTRATIVE (SG&A) EXPENSES. SG&A expenses increased to $20,983,000 in the three months ended June 30, 2003, up $1,495,000 or 8% from $19,488,000 in the three months ended June 30, 2002. This increase in expense primarily reflects a $1,246,000 increase in SG&A expenses related to the acquisition of Synavant. Excluding the results of Synavant, SG&A expenses decreased to $19,351,000 or 31% of revenues for the three months ended June 30, 2003, as compared to 34% of revenues for the three months ended June 30, 2002. Improvement in SG&A as a percentage of revenues primarily reflects the positive operating leverage attained through the Company’s acquisition of SAI, as well as the positive impact of the Company’s cost reduction actions in the third quarter of 2002 offset by an increase of amortization expense related to definite lived assets from acquisitions.

15

        RESEARCH AND DEVELOPMENT (R&D) EXPENSES. R&D expenses increased to $3,215,000 in the three months ended June 30, 2003, up $760,000 or 31% from $2,455,000 in the three months ended June 30, 2002. As a percentage of revenues, R&D expenses slightly increased to 5% in the three month period ended June 30, 2003 compared to 4% for the three months ended June 30, 2002. R&D expenses for the three months ended June 30, 2003 includes $198,000 of costs recognized from Synavant subsequent to the acquisition. Excluding the results of Synavant, R&D expenses increased $562,000 or 23% for the three months ended June 30, 2003. This increase relates to higher employment costs due to an increase in headcount from the acquisition of SAI.

        PROVISION FOR INCOME TAXES. The effective tax expense rate was 46% in the three months ended June 30, 2003 as compared to 36% for the three months ended June 30, 2002. In connection with the Synavant integration, the Company performed a reforecast of projected taxable income by jurisdiction and recognized a full valuation allowance on net operating loss carryforward for one of its foreign subsidiaries of approximately $608,000 which increased the effective tax expense rate by 6%. Prior to the acquisition of Synavant, the Company’s forecasted effective tax expense rate for the three months ended June 30, 2003 was 40%. In July 2002, the State of New Jersey enacted new tax legislation that adversely impacted the effective state tax rate of most companies operating in New Jersey. At June 30, 2002, the legislation had not yet been enacted and the effective tax rate originally reported for the three months ended June 30, 2002 was 36%.

SIX MONTHS ENDED JUNE 30, 2003 AND 2002

             REVENUES. Total revenues increased to $129,238,000 in the six months ended June 30, 2003, up $14,183,000 or 12% from $115,055,000 in the six months ended June 30, 2002. Total revenues for the six months ended June 30, 2003 includes $7,426,000 of revenue recognized from Synavant subsequent to the Company’s acquisition. Due to the timing of several large deals within the quarter, Synavant performed a substantial amount of services during the last two weeks of the quarter which caused a higher than expected amount of revenue to be recognized. Excluding the revenue recognized from Synavant, revenues increase $6,757,000 or 6% for the six months ended June 30, 2003 over the prior year period.

        License fee revenues decreased $170,000 or 3% to $5,315,000 in the six months ended June 30, 2003 from $5,485,000 in the six months ended June 30, 2002. License fee revenues as a percentage of total revenues were 4% in the six months ended June 30, 2003, as compared to 5% in the six months ended June 30, 2002. License fee revenues for the six months ended June 30, 2003 includes $86,000 of revenues recognized from Synavant subsequent to the Company’s acquisition. Excluding the results of Synavant, license fee revenues decreased $256,000 or 5% in the six months ended June 30, 2003 over the prior year period. License fees are, by nature, non-recurring items. The majority of license fees recognized during the six months ended June 30, 2003 related to licenses being recognized using the percentage-of-completion method as services were performed.

        Service revenues increased to $123,923,000 in the six months ended June 30, 2003, up $14,353,000 or 13% from $109,570,000 in the six months ended June 30, 2002. Service revenues as a percentage of total revenues were 96% in the six months ended June 30, 2003, compared to 95% in the six months ended June 30, 2002. Service revenues for the six months ended June 30, 2003 includes $7,340,000 of revenue recognized from Synavant subsequent to the acquisition. Excluding the results of Synavant, service revenues increased $7,013,000 or 6% compared to the same period for the prior year. The relative increase in service revenues reflects growth of approximately 20% in implementation revenue related to the integration work for our largest customer, growth of approximately 5% in our technical services as well as growth of more than 100% in our data business partially offset by decreases in low gross margin or reimbursable revenue. In addition, favorable foreign currency movements accounted for 2% of the period-on-period growth.

         COST OF REVENUES. Total cost of revenues increased to $64,601,000 in the six months ended June 30, 2003, an increase of $5,694,000 or 10% from $58,907,000 in the six months ended June 30, 2002. Total cost of revenues in the six months ended June 30, 2003 includes $4,858,000 of costs recognized from Synavant subsequent to the acquisition. Excluding the results of Synavant, cost of revenues increased $836,000 or 1% compared to the same period for the prior year.

        Cost of license fees increased to $2,283,000 in the six months ended June 30, 2003, an increase of $32,000 or 1% from $2,251,000 in the six months ended June 30, 2002. Cost of license fees for the six months ended June 30, 2003 is comprised of the amortization of capitalized and purchased software costs of $1,688,000 and third party vendor license fees of $595,000. Cost of license fees for the same period in 2002 is comprised of the amortization of capitalized and purchased software costs of $1,297,000 and third party vendor license fees of $954,000. The increase in amortization of capitalized and purchased software costs relates primarily to amortization of the assets obtained from the acquisition of SAI, which occurred in September 2002.

16

        Cost of services increased to $62,318,000 in the six months ended June 30, 2003, up $5,662,000 or 10% from $56,656,000 in the six months ended June 30, 2002. This increase was due primarily to the $4,858,000 incremental increase in cost of services related to Synavant’s operations. Excluding the results of Synavant, cost of services increased $804,000 or 1% in the six months ended June 30, 2003 compared to the prior year period. This increase is due to the additional costs from the increase in headcount due to the acquisition of SAI in September 2002 as well as additional outside consultants related to the integration work for our largest customer. These increases were offset by a decrease in low-gross margin or reimbursable revenue.

         GROSS MARGIN. Total gross margin for the six months ended June 30, 2003 was 50%, up from 49% for the six months ended June 30, 2002. For the reasons described above, the Synavant acquisition negatively impacted gross margin for the six months ended June 30, 2003 by 1%. Excluding the results of Synavant, total gross margin was 51% for the six months ended June 30, 2003.

        Gross margin for license fees was 57% in the six months ended June 30, 2003, down from 59% for the six months ended June 30, 2002. The decrease in gross margin was primarily impacted by decreasing license fee revenue as well as an increase in amortization of capitalized and purchased software costs which relates primarily to amortization of the assets obtained from the acquisition of SAI, which occurred in September 2002.

        Gross margin for services was 50% in the six months ended June 30, 2003, up from 48%. The Synavant acquisition negatively impacted gross margin for services for the six months ended June 30, 2003 by 1%. Excluding the impact of Synavant, gross margin for services was 51% in the six months ended June 30, 2003. This increase is driven by a decrease in the amount of low gross margin or reimbursable revenue, increase in implementation revenues of approximately 20% related to the integration work for our largest customer, increase in technical service revenues of approximately 5% as well as growth of more than 100% in our data business partially offset by additional costs from the increase in headcount due to the acquisition of SAI in September 2002 as well as additional outside consultants related to the integration work for our largest customer. Also contributing to margin improvement were the efficiencies gained from the Company’s cost reduction actions in the third quarter of 2002.

         SELLING, GENERAL AND ADMINISTRATIVE (SG&A) EXPENSES. SG&A expenses increased to $41,222,000 in the six months ended June 30, 2003, up $2,235,000 or 6% from $38,987,000 in the six months ended June 30, 2002. As a percentage of revenues, SG&A expenses decreased to 32% of revenues in the six months ended June 30, 2003, as compared with 34% of revenues in the six months ended June 30, 2002. The increase in SG&A reflects a $1,246,000 increase related to the acquisition of Synavant. Excluding the results of Synavant, SG&A increased $989,000 or 3%. This increase reflects the additional operating costs from the acquisition of SAI, higher employment costs, higher professional fees and amortization expense related to definite lived assets from acquisitions, partially offset by the impact of the Company’s cost reduction actions in the third quarter of 2002.

        RESEARCH AND DEVELOPMENT (R&D) EXPENSES. R&D expenses increased to $5,912,000 in the six months ended June 30, 2003, up $829,000 or 16% from $5,083,000 in the six months ended June 30, 2002. As a percentage of revenues, R&D expenses increased slightly to 5% in the six months ended June 30, 2003, up from 4% in the six months ended 2002. R&D expenses for the six months ended June 30, 2003 includes $198,000 of costs recognized from Synavant subsequent to the acquisition. Excluding the results of Synavant, R&D expenses increased $631,000 or 12% for the six months ended June 30, 2003. This increase relates to higher employment costs due to an increase in headcount from the acquisition of SAI.

        PROVISION FOR INCOME TAXES. The effective tax expense recorded in six months ended June 30, 2003 was 43% as compared with 36% in the six months ended June 30, 2002. In connection with the Synavant integration, the Company performed a reforecast of projected taxable income by jurisdiction and recognized a full valuation allowance on net operating loss carryforward for one of its foreign subsidiaries of approximately $608,000, which increased the effective tax expense rate by 3%. Prior to the acquisition of Synavant, the Company’s forecasted effective tax expense rate for the six months ended June 30, 2003 was 40%. In July 2002, the State of New Jersey enacted new tax legislation that adversely impacted the effective state tax rate of most companies operating in New Jersey.

LIQUIDITY AND CAPITAL RESOURCES

        We finance our operations primarily through cash generated by operations. Net cash provided by operating activities was $7,926,000 for the six months ended June 30, 2003, compared to $3,809,000 for the six months ended June 30, 2002. This increase in cash provided by operating activities was due primarily to increases in net income and cash collections from accounts receivable and a decrease in the amount of accrued restructuring payments offset by an increase in the amount of accrued expenses paid compared to the prior year period. The increase in accrued expenses paid related primarily to the payment of approximately $16 million of Synavant liabilities as of the acquisition date.

        Cash used in investing activities was $55,725,000 in the six months ended June 30, 2003, compared to $15,991,000 in the six months ended June 30, 2002. The increase of $39,734,000 is attributable to the acquisition of Synavant offset by lower purchases of property and equipment as well as no purchases of short term investments during the six months ended June 30, 2003 compared to the prior year period.

17

        Cash provided by financing activities was $2,279,000 in the six months ended June 30, 2003, compared to $2,010,000 in the six months ended June 30, 2002. The increase of $269,000 is attributable to an increase in stock option exercises during the six months ended June 30, 2003. Due to the timing of the disbursement of cash for the acquisition, the Company borrowed $5,000,000 from its line of credit, which was paid back from accounts receivable collections prior to June 30, 2003.

        At June 30, 2003, working capital was approximately $21,587,000. Total cash and investments were 9% of total assets as of June 30, 2003, compared with 37% as of December 31, 2002. The Company’s days sales outstanding in accounts receivable was 94 days as of June 30, 2003 compared with 73 days as of December 31, 2002. Excluding the impact of Synavant, the Company’s days sales outstanding as of June 31, 2003 was 61 days. We believe that available funds, anticipated cash flows from operations and our line of credit will satisfy our currently projected working capital and capital expenditure requirements, exclusive of cash required for possible acquisitions of businesses, products and technologies, for the next twelve to eighteen months.

        The Company regularly evaluates opportunities to acquire products or businesses complementary to our operations. Such acquisition opportunities, if they arise and are successfully completed, may involve the use of cash or equity instruments.

Contractual Obligations and Commitments

        The Company entered into a credit agreement as of June 16, 2003, in the amount of $30 million with JPMorgan Chase Bank as the agent. The credit agreement replaces the $15 million credit facility, which has been terminated. The credit agreement is available to finance working capital needs and possible future acquisitions. The terms of this agreement require us to maintain a minimum consolidated net worth, among other covenants, measured quarterly, which is equal to $130 million, plus 50% of net income earned after April 1, 2003 and 75% of net proceeds of any offering of new equity interests issued after June 30, 2003. This covenant effectively limits the amount of any cash dividends. The credit facility expires on July 1, 2005. At June 30, 2003, there were no borrowings outstanding under the agreement and the Company was in compliance with all of its covenant obligations.

        As of June 30, 2003, the Company did not have any material commitments for capital expenditures. Our principal commitments at June 30, 2003 consisted primarily of obligations under operating and capital leases as well as future minimum guarantees to certain vendors. Future minimum payments on these obligations are as follows:

As of June 30, 2003, letters of credit for approximately $996,000 were outstanding.

        The Company has an agreement with a venture capital fund with a commitment to contribute $1,000,000 to the fund, callable at the discretion of the general partner in $100,000 increments. As of June 30, 2003, $400,000 has been paid, with $600,000 of commitment remaining. The agreement has a termination date of December 11, 2010, subject to extension with the consent of a majority in interest of the limited partners.

FACTORS THAT MAY AFFECT FUTURE RESULTS

     OUR BUSINESS IS HEAVILY DEPENDENT ON THE PHARMACEUTICAL INDUSTRY

        Most of our customer relationship management (CRM), sales force effectiveness (SFE) and data products and services are currently used in connection with the marketing and sale of prescription-only drugs. This market is undergoing a number of significant changes. These include:

18

        We cannot assure you that we can respond effectively to any or all of these and other changes in the marketplace. Our failure to do so could have a material adverse effect on our business, operating results or financial condition.

     WE DEPEND ON A FEW MAJOR CUSTOMERS FOR A SIGNIFICANT PORTION OF OUR REVENUES

       Historically, a limited number of our customers have contributed a significant percentage of the Company’s revenues. The Company anticipates that its operating results in any given period will continue to depend significantly upon revenues from a small number of customers. The loss of any of these customers (which could include loss through mergers and acquisitions) could have a materially adverse effect on the Company’s business. We cannot make any assurances that we will retain our existing customers or attract new customers that would replace the revenue that could be lost if one or more of these customers failed to renew its agreement(s) with the Company.

     BUSINESS AND ECONOMIC PRESSURES ON OUR MAJOR CUSTOMERS MAY CAUSE A DECREASE IN DEMAND FOR OUR NEW PRODUCTS AND SERVICES

        Business and economic pressures on our major customers may result in budget constraints that directly impact their ability to purchase the Company’s new products and services offerings. We cannot assure you that any decrease in demand caused by these pressures will not have a material adverse effect on our business, operating results or financial condition.

     OUR LENGTHY SALES AND IMPLEMENTATION CYCLES MAKE IT DIFFICULT TO PREDICT OUR QUARTERLY REVENUES

        The selection of a CRM or SFE solution generally entails an extended decision-making process by our customers because of the strategic implications and substantial costs associated with a customer’s license or implementation of the solution. Given the importance of the decision, senior levels of management of our customers are often involved in the process and, in some instances, its board of directors may also be involved. As a result, the decision-making process typically takes nine to eighteen months, and in certain cases longer. Accordingly, we cannot fully control or predict the timing of our execution of contracts with customers.

        In addition, an implementation process of three to six or more months before the software is rolled out to a customer’s sales force is customary. However, if a customer were to delay or extend its implementation process, our quarterly revenues may decline below expected levels and could adversely affect our results of operations.

     OUR FIXED COSTS MAY LEAD TO FLUCTUATIONS IN OUR QUARTERLY OPERATING RESULTS IF REVENUES FALL BELOW EXPECTATIONS

        We establish our expenditure levels for product development, sales and marketing and some of our other operating expenses based in large part on our expected future revenues and anticipated competitive conditions. In particular, we frequently add staff in advance of new business to permit adequate time for training. If the new business is subsequently delayed, canceled or not awarded, we will have incurred expenses without the associated revenues. In addition, we may increase sales and marketing expenses if competitive pressures become greater than originally anticipated. Since only a small portion of our expenses varies directly with our actual revenues, our operating results and profitability are likely to be adversely and disproportionately affected if our revenues fall below our targeted goals or expectations.

     WE MAY BE UNABLE TO SUCCESSFULLY INTRODUCE NEW PRODUCTS OR RESPOND TO TECHNOLOGICAL CHANGE

        The market for CRM and SFE products changes rapidly because of frequent improvements in computer hardware and software technology. Our future success will depend, in part, on our ability to:

19

        We cannot assure you that we will successfully develop and market new products or product enhancements that respond to technological advances in the marketplace, or that we will do so in a timely fashion. We also cannot assure you that our products will adequately and competitively address the needs of the changing marketplace.

        Competition for software products has been characterized by shortening product cycles. We may be materially and adversely affected by this trend if the product cycles for our products prove to be shorter than we anticipate. If that happens, our business, operating results or financial condition could be adversely affected.

        To remain competitive, we also may have to spend more of our revenues on product research and development than we have in the past. As a result, our results of operations could be materially and adversely affected.

        Further, our software products are technologically complex and may contain previously undetected errors or failures. We cannot assure you that, despite our testing, our new products will be free from significant errors. Software errors could cause delays in the commercial release of products until the errors have been corrected. Software errors may cause us to be in breach of our agreements with customers, which could result in termination of the agreements and monetary damages. Software errors may cause damage to our reputation and cause us to commit significant resources to their correction. Errors that result in termination of agreements, monetary damages, losses or delays could have a material adverse effect on our business, operating results or financial condition.

     INCREASED COMPETITION MAY RESULT IN PRICE REDUCTIONS AND DECREASED DEMAND FOR OUR PRODUCTS AND SERVICES

        There are a number of other companies that sell CRM and SFE products and related services that specifically target the pharmaceutical industry, including competitors that are actively selling CRM and SFE software products in more than one country and competitors that also offer CRM and SFE support services. Some of our competitors and potential competitors are part of large corporate groups and have significantly greater financial, sales, marketing, technology and other resources than we have.

        While we believe that the CRM and SFE software products and/or services offered by most of our competitors do not address the variety of pharmaceutical customer needs that our solutions address, increased competition may require us to reduce the prices for our products and services. Increased competition may also result in decreased demand for our products and services.

        We believe our ability to compete depends on many factors, some of which are beyond our control, including:

Any one of these factors can lead to price reductions and/or decreased demand and we cannot assure you that we will be able to continue to compete successfully or that competition will not have a material adverse effect on our business, operating results or financial condition.

     WE MAY NOT BE ABLE TO COMPETE EFFECTIVELY IN THE INTERNET-RELATED PRODUCTS AND SERVICES MARKET NOR CAN WE PROVIDE ASSURANCES THAT THE DEMAND FOR INTERNET-RELATED PRODUCTS AND SERVICES WILL INCREASE

        The success of parts of our business will depend, in part, on our ability to continue developing Internet-related products and responding to technological advances and changing commercial uses of the Internet. We cannot assure you that our Internet-related products and services will adequately respond to such technological advances and changing uses. Nor can we assure you that the demand for Internet-related products and services will increase.

     OUR INTERNATIONAL OPERATIONS HAVE RISKS THAT OUR DOMESTIC OPERATIONS DO NOT

        The sale of our products and services in foreign countries accounts for, and is expected in the future to account for, a material part of our revenues. These sales are subject to risks inherent in international business activities, including:

20

     WE MAY FACE RISKS ASSOCIATED WITH OUR ACQUISITIONS

        Our business may be materially and adversely affected as a result of the risks associated with our acquisitions including our recent acquisitions of Synavant and SAI. As part of our business strategy, in the future we may also acquire businesses that offer complementary products, services or technologies. These acquisitions are accompanied by substantial risks, including:

        These factors could have a material adverse effect on our revenues and earnings. We expect that the consideration paid for future acquisitions, if any, could be in the form of cash, stock, rights to purchase stock, or a combination of these. To the extent that we issue shares of stock or other rights to purchase stock in connection with any future acquisition, existing shareholders will experience dilution and potentially decreased earnings per share.

        We are currently integrating the Synavant business with our other operations. While we have had success integrating acquired entities into our operations in the past, we cannot guarantee that we will successfully integrate this new business into our operations.

     AN INABILITY TO MANAGE GROWTH COULD ADVERSELY AFFECT OUR BUSINESS

        To manage our growth effectively we must continue to strengthen our operational, financial and management information systems and expand, train and manage our work force. However, we may not be able to do so effectively or on a timely basis. Failure to do so could have a material adverse effect upon our business, operating results or financial condition.

     WE MAY FACE RISKS ASSOCIATED WITH EVENTS WHICH MAY AFFECT THE WORLD ECONOMY

        The terrorist attacks of September 11, 2001 and subsequent world events weakened the world economy. While we did not experience any material impact to our business during the time period immediately following September 11, 2001, we cannot assure you that the resulting impact which the terrorist attacks, threat of future terrorist activity, current U.S. military action in the Middle East and elsewhere, or hostilities in the Middle East, Asia and other geographical areas, had or may have on the U.S. and world economies will not adversely affect our business or the businesses of our customers.

     CATASTROPHIC EVENTS COULD NEGATIVELY AFFECT OUR INFORMATION TECHNOLOGY INFRASTRUCTURE

        The efficient operation of our business, and ultimately our operating performance, depends on the uninterrupted use of our critical business and information technology systems. Many of these systems require the use of specialized hardware and other equipment that is not readily available. Although we maintain these systems at more than one location, a natural disaster, a fire or other catastrophic event at any of these locations could result in the destruction of these systems. In such an event, the replacement of these systems and restoration of archived data and normal operation of our business could take several days to several weeks, or more. During the intervening period when our critical business and information technology systems are fully or partially inoperable, our ability to conduct normal business operations could be significantly and adversely impacted and as a result our business, operating results and financial conditions could be adversely affected.

21

     OUR SUCCESS DEPENDS ON RETAINING OUR KEY SENIOR MANAGEMENT TEAM AND ON ATTRACTING AND RETAINING QUALIFIED PERSONNEL

        Our future success depends, to a significant extent, upon the contributions of our executive officers and key sales, technical and customer service personnel. Our future success also depends on our continuing ability to attract and retain highly qualified technical and managerial personnel. Due to competition for such personnel, we have at times experienced difficulties in recruiting qualified personnel and we may experience such difficulties in the future. Any such difficulties could adversely affect our business, operating results or financial condition.

     OUR BUSINESS DEPENDS ON PROPRIETARY TECHNOLOGY THAT WE MAY NOT BE ABLE TO PROTECT COMPLETELY

        We rely on a combination of trade secret, copyright and trademark laws, non-disclosure and other contractual agreements and technical measures to protect our proprietary technology. We cannot assure you that the steps we take will prevent misappropriation of this technology. Further, protective actions we have taken or will take in the future may not prevent competitors from developing products with features similar to our products. In addition, effective copyright and trade secret protection may be unavailable or limited in certain foreign countries. In response to a request by our customers, we have also on occasion entered into agreements which require us to place our source code in escrow to secure our service and maintenance obligations.

        Further, while we believe that our products and trademarks do not infringe upon the proprietary rights of third parties, third parties may assert infringement claims against us in the future that may result in the imposition of damages or injunctive relief against us. In addition, any such claims may require us to enter into royalty arrangements. Any of these results could materially and adversely affect our business, operating results or financial condition.

     IF OUR THIRD PARTY VENDORS ARE UNABLE TO SUCCESSFULLY RESPOND TO TECHNOLOGICAL CHANGE OR IF WE DO NOT MAINTAIN OUR RELATIONSHIPS WITH THIRD PARTY VENDORS, INTERRUPTIONS IN THE SUPPLY OF OUR PRODUCTS MAY RESULT

        Some of our software is provided by third party vendors. If our third party vendors are unable to successfully respond to technological change or if our relationships with certain third party vendors are terminated, we may experience difficulty in replacing the functionality provided by the third party software currently offered with our products. Although we believe there are other sources for all of our third party software, any significant interruption in the supply of these products could adversely impact our sales unless and until we can secure another source. The absence of or any significant delay in the replacement of functionality provided by third party software in our products could materially and adversely affect our sales.

     THE RESULTS DERIVED FROM CURRENT AND FUTURE STRATEGIC RELATIONSHIPS MAY PROVE TO BE LESS FAVORABLE THAN ANTICIPATED

        We are involved in a number of strategic relationships with third parties and are frequently pursuing others. Should these relationships, or any of them, prove to be more costly than anticipated or fail to meet revenue expectations or other anticipated synergies, we cannot guarantee that such events will have no material impact upon our business, operating results or financial condition.

     OUR DATA SOLUTIONS ARE DEPENDENT UPON STRATEGIC RELATIONSHIPS WHICH, IF NOT MAINTAINED, COULD UNDERMINE THE CONTINUED VIABILITY OF THESE SOLUTIONS

        Our data and analytics solutions are sourced, in part, from data provided through strategic relationships. The termination of any of these relationships could diminish the breadth or depth of our data solutions and we cannot guarantee that this would not negatively impact our business, operating results or financial condition.

     FEDERAL AND STATE LAWS AND REGULATIONS COULD DEPRESS THE DEMAND FOR SOME OF OUR SOLUTIONS

        While we believe our data and analytics solutions are not violative of current federal or state laws and regulations pertaining to patient privacy or health information, including the Health Insurance Portability and Accountability Act of 1996 (HIPAA), we cannot guarantee that future laws or regulations or interpretations of existing laws and statutes will not impact negatively upon our ability to market these solutions or cause a decrease in demand for such solutions from customers that see an increased risk in any such new laws or regulations.

     GOVERNMENTAL REGULATION MAY MATERIALLY AND ADVERSELY AFFECT THE COMPANY’S ABILITY TO DISTRIBUTE CONTROLLED SUBSTANCES THROUGH THE MAIL

        Through the interactive marketing business we acquired in the Synavant acquisition, we currently distribute controlled substances to doctors’ offices through the mail as part of certain interactive marketing programs provided on behalf of pharmaceutical manufacturers.  It is important to the business that this practice of distributing prescription-only drugs continues. Future legislation may restrict our ability to provide these types of services.  If any such legislation is enacted, it could have a material and adverse effect on our business, operating results and financial condition.

22

     DIFFICULTIES IN SUBLEASING, SELLING OR OTHERWISE DISPOSING OF CERTAIN OF OUR FACILITIES MAY NEGATIVELY IMPACT UPON OUR EARNINGS

        We are currently marketing our Piscataway, New Jersey facility. We also expect to sublease all or a portion of certain other facilities, including facilities acquired as part of the Synavant acquisition. If the recent real estate downturn continues, it could negatively impact upon our ability to effectively market these facilities. An inability to successfully dispose or sublet, as applicable, any of these facilities or to obtain favorable pricing or sublease terms could negatively impact our earnings.

     UNANTICIPATED CHANGES IN OUR ACCOUNTING POLICIES MAY BE REQUIRED BECAUSE OF MANDATES BY ACCOUNTING STANDARDS SETTING ORGANIZATIONS AND COULD HAVE A MATERIAL IMPACT ON OUR FINANCIAL STATEMENTS

        In reporting our financial results we rely upon the accounting policies and standards then in effect at the time of our report. Future regulations, standards or interpretations may require us to adjust or restate financial results previously reported. A required restatement could have an unfavorable impact upon past financial results or current comparison to previous results.

     PROVISIONS OF OUR CHARTER DOCUMENTS AND NEW JERSEY LAW MAY DISCOURAGE AN ACQUISITION OF DENDRITE

        Provisions of our Restated Certificate of Incorporation, as amended, our By-laws, as amended, and New Jersey law may make it more difficult for a third party to acquire us. For example, the Board of Directors may, without the consent of the stockholders, issue preferred stock with rights senior to those of the common stock. In addition, the Company has a Shareholder Rights Plan which may limit the ability of a third party to attempt a hostile acquisition of the Company.

     OUR COMMON STOCK MAY BE SUBJECT TO PRICE FLUCTUATIONS

        The market price of our common stock may be significantly affected by the following factors:

        Further, the stock market has experienced on occasion extreme price and volume fluctuations. The market prices of the equity securities of many technology companies have been especially volatile and often have been unrelated to the operating performance of such companies. These broad market fluctuations may have a material adverse effect on the market price of our common stock.

ITEM 4.      Controls and Procedures

The Company’s Chief Executive Officer and Chief Financial Officer, with the assistance of other members of the Company’s management, have evaluated the effectiveness of the Company’s disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on such evaluation, the Company’s Chief Executive Officer and Chief Financial Officer have concluded that the Company’s disclosure controls and procedures are effective.

The Company’s Chief Executive Officer and Chief Financial Officer have also concluded that there have not been any changes in the Company’s internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

23

PART II.      OTHER INFORMATION

ITEM 4.     Submission of Matters to a Vote of Security Holders

        Based on these voting results, each of the directors nominated was elected.

ITEM 6.      Exhibits and Reports on Form 8-K

      (i)   Exhibits

The Company filed a Current Report on Form 8-K on July 1, 2003, pursuant to “Item 2. Acquisition or Disposition of Assets” and “Item 7. Financial Statements, Pro Forma Financial Information and Exhibits” relating to its acquisition of Synavant Inc.

The Company filed a Current Report on Form 8-K on June 20, 2003, pursuant to “Item 5. Other Events and Regulation FD Disclosure” and “Item 7. Financial Statements, Pro Forma Financial Information and Exhibits” relating to a credit agreement by and among the Company, certain lenders and JPMorgan Chase Bank.

The Company filed a Current Report on Form 8-K on May 20, 2003, pursuant to “Item 5. Other Events and Regulation FD Disclosure” and “Item 7. Financial Statements, Pro Forma Financial Information and Exhibits” relating to an amendment to the Agreement and Plan of Merger by and among the Company, Synavant Inc. and Amgis Acquisition Co. and a promissory note by and between the Company and Synavant Inc.

The Company filed a Current Report on Form 8-K on May 19, 2003, pursuant to “Item 5. Other Events and Regulation FD Disclosure” and “Item 7. Financial Statements, Pro Forma Financial Information and Exhibits” relating to an amendment to the Agreement and Plan of Merger by and among the Company, Synavant Inc. and Amgis Acquisition Co.

The Company filed a Current Report on Form 8-K on May 12, 2003, pursuant to “Item 5. Other Events and Regulation FD Disclosure” and “Item 7. Financial Statements, Pro Forma Financial Information and Exhibits” relating to the Agreement and Plan of Merger by and among the Company, Synavant Inc. and Amgis Acquisition Co.

The Company furnished a Current Report on Form 8-K on April 24, 2003, pursuant to “Item 7. Financial Statements, Pro Forma Financial Information and Exhibits,” “Item 9. Regulation FD Disclosure” and “Item 12. Results of Operations and Financial Condition” relating to its financial results for the first quarter of 2003.

24

Signatures

        Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: August 13, 2003

25